Pharm
Tumor Lysis Syndrome
search
Tumor Lysis Syndrome
See Also
Oncologic Emergency
Blast Crisis
Chemotherapy
Definitions
Tumor Lysis Syndrome
Acute tumor cell lysis post-
Chemotherapy
or radiation for tumor debulking
Less commonly, tumor lysis may occur spontaneously with inflammatory cancers
Pathophysiology
Aggressive treatment for high grade
Lymphoma
,
Acute Lymphoblastic Leukemia
or high tumor burden
Results in massive tumor lysis
Massive tumor lysis releases breakdown products
Increased
Potassium
(
Hyperkalemia
)
Most serious lab abnormality in Tumor Lysis Syndrome
Decreased
Calcium
(
Hypocalcemia
)
Most common
Electrolyte
abnormality in tumor lysis
Lysed cells bind
Free Calcium
and
Phosphorus
increases
Increased Phosphate (
Hyperphosphatemia
)
Risk of
Calcium Phosphate
deposition in
Kidney
s
Increased risk when sPh x sCa >70 (mg/dl)^2
Increased
Uric Acid
(
Hyperuricemia
)
Purine
Nucleic Acid
s enzymatically degraded by xanthine oxidase
May form crystals and result in
Acute Kidney Injury
Tumor breakdown products overwhelm excretion mechanism
Acute Renal Failure
(secondary to
Hyperuricemia
and
Calcium Phosphate
crystallization)
Risk Factors
Hematologic Malignancy
High grade
Lymphoma
Acute Lymphoblastic Leukemia
Solid cancers with high tumor burden (less common)
Renal Insufficiency
Lactate Dehydrogenase
Increased
Causes
Most common associated tumors
Aggressive
Chemotherapy
induction (within first 5-7 days)
Less commonly,
Radiation Therapy
and
Biologic Agent
s may also cause tumor lysis
Acute presentation of undiagnosed rapidly growing tumor
Acute Lymphoblastic Leukemia
High grade
Lymphoma
Inflammatory
Breast Cancer
with high rate of proliferation
Findings
Presentations related
Hyperkalemia
,
Acute Renal Failure
Gene
ral symptoms
Nausea
or
Vomiting
Diarrhea
Lethargy
Decreased
Urine Output
Cardiac findings
Congestive Heart Failure
Dysrhythmia
Syncope
Neurologic findings
Seizure
s
Muscle
cramps and myalgias
Tetany
Labs
Chemistry panel
Renal Function
tests:
Acute Renal Failure
Typically due to
Uric Acid
and
Calcium Phosphate
precipitation in the renal tubule
Blood Urea Nitrogen
increased
Serum Creatinine
increased
Serum bicarbonate or ABG
Metabolic Acidosis
Serum Phosphate
Hyperphosphatemia
Serum Potassium
Hyperkalemia
Serum Calcium
Hypocalcemia
Serum
Uric Acid
Hyperuricemia
Lactate Dehydrogenase
Increased
Lactate Dehydrogenase
in Tumor Lysis
Diagnostics
Electrocardiogram
(EKG)
See
Hyperkalemia Related EKG Changes
Diagnosis
Cairo-Bishop Definition
Criteria: Two present in one 24 hour period (3 days before of 7 days after
Chemotherapy
initiation)
Serum Calcium
<=7 mg/dl or 25% decrease from baseline
Serum Phosphorus
>=4.5 mg/dl in adults (>6.5 mg/dl children) or 25% increase from baseline
Serum Potassium
>=6 mEq/L or 25% increase from baseline
Uric Acid
>=8 mg/dl or 25% increase from baseline
Interpretation: Clinical Tumor Lysis Syndrome
Two lab criteria present AND
One of the following
Cardiac Arrhythmia
or sudden death
Serum Creatinine
>= 1.5 times upper limit of normal for age
Seizure Disorder
Modifications
Some include symptomatic
Hypocalcemia
alone as full diagnostic criteria for tumor lysis
Other
Acute Kidney Injury
definitions may be substituted for "
Serum Creatinine
>1.5 times normal"
References
Cairo (2004) Br J Haematol 127(1):3-11 [PubMed]
Management
Continuous cardiac monitoring
Hospitalization to
Intensive Care
unit at a facility where
Hemodialysis
and inpatient oncology are available
Consult oncology
Aggressive
Intravenous Fluid
hydration (
Normal Saline
)
Goal
Urine Output
: 100 ml/hour
Monitor elecrolytes every 6 hours
Serum
Electrolyte
s (
Serum Potassium
,
Renal Function
tests,
Serum Calcium
,
Serum Phosphate
, serum
Uric Acid
)
Manage
Electrolyte
abnormalities
See
Hyperkalemia Management
See
Hypocalcemia
See
Hyperuricemia
See
Hyperphosphatemia
See
Acute Renal Failure
Hyperkalemia Management
See
Hyperkalemia Management
Most emergent of the
Electrolyte
abnormalities
Hyperphosphatemia
management
Restrict phosphate intake
Phosphate Binder
s (e.g. aluminum hydroxide,
Calcium Carbonate
,
Sevelamer
)
Hemodialysis
Hypocalcemia
management
Hypocalcemia
is secondary to
Hyperphosphatemia
Do not start
Calcium Replacement
unless
Hyperphosphatemia
has corrected
Risk of increased
Calcium Phosphate
crystals and worsening
Acute Renal Failure
Exceptions (in which cases
Calcium
administration is indicated
Hypocalcemia
related complications (e.g.
Seizure
s, CHF)
Hyperkemia related EKG changes
Hyperuricemia
management
Rasburicase (Elitek)
Dose: 0.2 mg/kg in 50 ml
Normal Saline
over 30 minutes daily for 5-7 days
Preferred in moderate to severe tumor lysis
Recombinant form of urate oxidase (uricase) that converts
Uric Acid
to allantoin
Allantoin is inactive, 10 fold more soluble than
Uric Acid
, and much more easily renally excreted
Contraindicated in
G6PD Deficiency
(screen high risk populations)
Dopes not prevent
Renal Failure
or decrease mortality
Allopurinol
Used preventively (prior to
Chemotherapy
)
Blocks
Nucleic Acid
metabolism to
Uric Acid
Reduces future
Uric Acid
production
Does NOT affect
Uric Acid
already produced
Avoid in ill patients (use rasburicase)
Alkalinizing urine in not recommended in most cases
No supporting data for
Urine Alkalinization
with
Sodium Bicarbonate
Associated with renal
Calcium Phosphate
crystal formation
Hemodialysis
See
Hemodialysis
for indications
Prevention
Anticipate Tumor Lysis Syndrome
Pretreatment with Intravenous hydration and maintain adequate
Urine Output
Pretreatment with
Allopurinol
to reduce baseline serum
Uric Acid
levels
Pretreatment - limit intake of
Potassium
and
Phosphorus
(3 days before and 7 days after initiation)
References
Aurora and Herbert in Majoewsky (2013) EM:Rap 13(10): 1-4
Long, Long and Koyfman (2020) Crit Dec Emerg Med 34(11): 17-24
Shelby (2015) Crit Dec Emerg Med 29(6): 2-8
Higdon (2006) Am Fam Physician 74:1873-80 [PubMed]
Higdon (2018) Am Fam Physician 97(11):741-8 [PubMed]
Zuckerman (2012) Blood 120(10): 1993-2002 [PubMed]
Type your search phrase here